Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:3
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 53 条
  • [1] Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study
    Assmann, G.
    Schulte, H.
    Cullen, P.
    Seedorf, U.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (12) : 925 - 932
  • [2] Association Between Family History and Coronary Heart Disease Death Across Long-Term Follow-Up in Men The Cooper Center Longitudinal Study
    Bachmann, Justin M.
    Willis, Benjamin L.
    Ayers, Colby R.
    Khera, Amit
    Berry, Jarett D.
    [J]. CIRCULATION, 2012, 125 (25) : 3092 - 3098
  • [3] A Modern Approach to Dyslipidemia
    Berberich, Amanda J.
    Hegele, Robert A.
    [J]. ENDOCRINE REVIEWS, 2022, 43 (04) : 611 - 653
  • [4] LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
    Bogsrud, Martin P.
    Graesdal, Asgeir
    Johansen, Dan
    Langslet, Gisle
    Hovland, Anders
    Arnesen, Kjell-Erik
    Mundal, Liv J.
    Retterstol, Kjetil
    Wium, Cecilie
    Holven, Kirsten B.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (02) : 279 - 286
  • [5] Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment
    Carr, Stuart S.
    Hooper, Amanda J.
    Sullivan, David R.
    Burnett, John R.
    [J]. PATHOLOGY, 2019, 51 (02) : 148 - 154
  • [6] Catapano Alberico L, 2017, Rev Esp Cardiol (Engl Ed), V70, P115, DOI 10.1016/j.rec.2017.01.002
  • [7] Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ? Do They Make a Difference? Can We See the Future?
    Cooney, Marie Therese
    Dudina, Alexandra
    D'Agostino, Ralph
    Graham, Ian M.
    [J]. CIRCULATION, 2010, 122 (03) : 300 - 310
  • [8] Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction
    Cui, Yuxia
    Li, Sufang
    Zhang, Feng
    Song, Junxian
    Lee, Chongyou
    Wu, Manyan
    Chen, Hong
    [J]. CLINICAL CARDIOLOGY, 2019, 42 (03) : 385 - 390
  • [9] Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
    Deshmukh, Harshal A.
    Colhoun, Helen M.
    Johnson, Toby
    McKeigue, Paul M.
    Betteridge, D. John
    Durrington, Paul N.
    Fuller, John H.
    Livingstone, Shona
    Charlton-Menys, Valentine
    Neil, Andrew
    Poulter, Neil
    Sever, Peter
    Shields, Denis C.
    Stanton, Alice V.
    Chatterjee, Aurobindo
    Hyde, Craig
    Calle, Roberto A.
    DeMicco, David A.
    Trompet, Stella
    Postmus, Iris
    Ford, Ian
    Jukema, J. Wouter
    Caulfield, Mark
    Hitman, Graham A.
    [J]. JOURNAL OF LIPID RESEARCH, 2012, 53 (05) : 1000 - 1011
  • [10] Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia
    Ellis, Katrina L.
    Perez de Isla, Leopoldo
    Alonso, Rodrigo
    Fuentes, Francisco
    Watts, Gerald F.
    Mata, Pedro
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1029 - 1039